Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	135.77	81.46	186.98	220.94	70.1	24.55
Short-Term Investments	0	44.48	3.92	23.13	48.1	66.82
Cash & Cash Equivalents	135.77	125.94	190.9	244.07	118.2	91.36
Cash Growth	7.81%	-34.03%	-21.79%	106.49%	29.37%	-
Other Current Assets	5.31	7.6	13.53	5.94	2.03	1.01
Total Current Assets	141.08	133.55	204.42	250.02	120.23	92.37
Property, Plant & Equipment	9.82	12.51	14.97	14.91	16.09	15.18
Long-Term Investments	0	0	15.11	0	10.02	0
Other Long-Term Assets	0.63	0.63	0.87	0.38	0.19	0.18
Total Long-Term Assets	10.44	13.15	30.95	15.29	26.29	15.36
Total Assets	151.53	146.69	235.37	265.3	146.52	107.73
Accounts Payable	2.52	4.74	3.02	3.31	3.77	2.98
Deferred Revenue	1.31	9.44	7.64	12	0	0
Current Debt	3.24	3.14	2.91	2.51	2.45	1.25
Other Current Liabilities	16.84	15.81	25.39	12.46	7.6	3.26
Total Current Liabilities	23.91	33.13	38.96	30.27	13.82	7.49
Long-Term Debt	7.9	9.43	11.55	10.5	11.88	12.61
Other Long-Term Liabilities	27.64	0.23	0.13	4.49	3.64	0.86
Total Long-Term Liabilities	35.54	9.66	11.68	14.99	15.51	13.47
Total Liabilities	59.45	42.79	50.64	45.26	29.33	20.96
Total Debt	11.14	12.57	14.46	13.01	14.33	13.86
Debt Growth	-11.42%	-13.01%	11.13%	-9.24%	3.37%	-
Retained Earnings	-486.8	-399.12	-303.07	-174.74	-66.2	-13.93
Comprehensive Income	0.55	0.4	0.45	-0.19	-0.12	0
Shareholders' Equity	92.08	103.9	184.73	220.04	-64.89	-13.75
Net Cash / Debt	124.64	113.37	176.44	231.07	103.87	77.5
Net Cash / Debt Growth	9.94%	-35.75%	-23.64%	122.46%	34.03%	-
Net Cash Per Share	1.94	2.66	4.43	23.13	51.75	6.98
Working Capital	117.18	100.42	165.47	219.74	106.41	84.88
Book Value Per Share	1.43	2.43	4.63	22.03	-32.33	-1.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).